Intensive fibrosis in the glomerular microenvironment is a prominent feature of diabetic nephropathy. Cannabinoid receptor 1 (CB1R) reportedly mediates diabetes-induced renal injury. However, studies on the molecular events underlying CB1R promotion of renal dysfunction are limited. This study is undertaken to investigate whether CB1R signaling via Ras or PPARγ pathway regulates mesangial fibrosis in diabetic kidneys. In streptozotocin-induced diabetic rats, hyperglycemia induced glomerular hypertrophy and fibrosis in association with increased IL-1β, fibronectin, and CB1R expressions and reduced PPARγ2 signaling. CB1R transgenic mice gained kidney weight, and renal glomeruli strongly displayed IL-1β and fibrotic matrices. Disruption of CB1R by antisense oligonucleotides or inverse agonist AM251 restored PPARγ2 signaling and reduced the promotional effects of hyperglycemia on the expression of fibrogenic transcription factor c-Jun, inflammation regulator SOCS3, proinflammatory cytokines, and accumulation of fibrotic matrix. PPARγ agonist rosiglitazone reduced the hyperglycemia-mediated
Introduction
Diabetes mellitus is an important etiological cause of kidney diseases [1] . Excessive extracellular matrix in glomerular compartments that disrupts renal microarchitectural integrity contributes to diabetic nephropathy [2] . Hyperglycemia reportedly augments inflammation reactions and impedes tissue homeostasis and integrity [3, 4] . The molecular events in the hyperglycemia-induced inflammation and fibrosis in glomerular compartments warrant characterization.
Type 1 cannabinoid receptor (CB1R) is a member of the Gi/o-protein-coupled receptor family found to regulate adipogenesis [5] , bone remodeling [6] , neurite growth [7] , and liver fibrosis [8] . Activation of CB1R signaling accelerates renal damage and urinary albumin excretion in diabetic animals [9] and renal tubular cell apoptosis [10] . Loss of CB1R signaling alleviates hyperglycemia-mediated oxidative stress and renal cell apoptosis [11] . Moreover, CB1R signaling reportedly regulates inflammation reactions in various tissues exposed to deleterious stress. Activation of CB1R increases endoplasmic reticulum stress and inflammatory cytokine expression in hepatic stellate cells [12] . CB1R antagonism reduces the diabetes-mediated inflammation and dysfunction in cardiac tissue [13] . However, the molecular mechanism underlying CB1R promotion of renal fibrosis has had limited studies.
Loss of PPARγ signaling contributes to the pathogenesis of renal disorders. Activation of PPARγ improves diabetesmediated urinary albumin excretion and renal deterioration [14] and age-induced renal damage [15] . CB1R regulation of PPARγ pathway protects neural cells from the adverse effects of inflammatory stress [16] . CB1R reportedly activates Ras pathways and regulates smooth muscle cell proliferation [17] . We have previously demonstrated that Ras signaling in mesangial cells actively responded to high glucose stress [18] . We hypothesized that CB1R signaling was involved in hyperglycemia-mediated perturbation of Ras or PPARγ pathway and promoted inflammation and fibrosis reactions in mesangial cells.
The purposes of this study were undertaken to investigate whether excessive extracellular matrix deposition or inflammatory cytokine secretion in diabetic renal glomeruli was linked to CB1R signaling and tested whether modulation of CB1R signaling affected diabetes-induced glomerular fibrosis. We also investigated whether CB1R changed Ras or PPARγ signaling in renal mesangial cell cultures exposed to high glucose.
Materials and methods

Streptozotocin-induced diabetes
The use of experimental animals was in accordance with the guidelines of the IACUC, Chang Gung Memorial Hospital and the Association for Assessment and Accreditation of Laboratory Animal Care International. Male Wistar rats (3 months old) were given intraperitoneal streptozotocin (50 mg/kg). Two weeks after injection, animals that had fasting blood glucose levels of 200-300 mg/dL were selected for studies and given insulin to equalize blood glucose, as previously described [19] . Animals were euthanized by an overdose of chloral hydrate at 2 weeks (n=6), 5 weeks (n= 6), or 8 weeks (n=6) after induction of diabetes, and renal tissues were dissected for studies.
CB1R transgenic mice
The PGK promoter and full-length CB1R cDNA were cloned from a cDNA library by PCR. The cDNAs were inserted into the pUSE expression vector, and the linear hPGK-CB1R-BGH poly-A cDNAs were cloned. The constructs were transferred into fertilized eggs from FVB/N mice and then transferred into ICR foster mothers, as previously described [20] . Transgenic mice were bred in a specific pathogen-free condition and genotyped by PCR using specific primers (Supplemental data 1). The kidneys of 2-month (n=6) and 9-month (n=9) wild-type and transgenic male mice were dissected and analyzed.
In vivo oligonucleotide and antagonist treatments CB1R antisense (CB1R-AS) and sense (CB1R-S) oligonucleotides with end-capped phosphorothioate modification were synthesized (Bio Basic Inc; Ontario, Canada). Diabetic rats were given intraperitoneal vehicle alone (n=6), 20 μg/kg per day CB1R-AS (n=6), or 20 μg/kg per day CB1R-S (n=6) for five consecutive weeks. Control rats (n=6) were given saline. In some experiments, diabetic rats were given intraperitoneal CB1R inverse agonist AM251 (Tocris Bioscience) at 50 μg/ kg per day (n=6) or 250 μg/kg per day (n=6) or were given intraperitoneal PPARγ agonist rosiglitazone (Camay) at 3 mg/kg per week (n=6) for 5 weeks.
Blood biochemistry
Serum levels of HbA1c (Primus Diagnostics, Kansas City, MO) and glucose (Dade Behring Inc., Newark, NJ) were measured according to the manufacturer's instructions. Glucose, triglyceride, GOT, and creatinine levels in blood were detected using serum biochemistry chips (FujiFilm).
Laser capture microdissection
Glomerular tissues (4-μm sections) were harvested using a VERITAS™ laser capture dissection system (Arcturus Bioscience Inc., CA), as described previously [21] . Two hundred glomeruli from six sections of each rat in each group were dissected for extraction of total RNA.
Quantification of mRNA expression profiles
Extraction of total RNA in whole renal tissue, isolated glomerular tissues or mesangial cell cultures was performed as described previously [21] . Differential mRNA expression profiles of whole renal tissues between diabetes and normal control groups were analyzed using TaqMan ® Gene Signature PCR Array Plate (Applied Biosystems), according to the manufacturer's instructions. Briefly, aliquots of total RNA were reversely transcribed using High-Capacity cDNA Reverse Transcription Kits. cDNA was amplified using TaqMan ® Universal PCR Master Mix, TaqMan ® Gene Expression Assay Kits, and ABI 7300 Detection System (Applied Biosystems). The change in expression was calculated as 2
−ΔΔCt
, where ΔΔCt=ΔCt DM −ΔCt NC and ΔCt= Ct target −Ct β-actin. In some experiments, mRNA expression of CB1R, IL-1β, fibronectin, PPARγ2, IL-6, TNFα, TGF-β1, cJun, and SOCS3 in renal glomerular tissues and mesangial cell cultures were quantified by RT-PCR protocols, as described previously [21] . Primers were designed and prepared by customized synthesis (Supplemental data 1).
Histomorphometry and immunohistochemistry
Periodic acid-Schiff staining (PAS) of renal tissues was performed according to the manufacturer's instructions (SigmaAldrich, St Louis, MO). The areas of glomeruli and PASpositive regions of ten glomeruli from each section were randomly selected for microscopy at ×400 magnification and quantified by use of Image-Pro ® Plus image-analysis software (Media Cybernetics, Silver Spring, MD). Glomerular volume was calculated, as previously described [21] . Sections were also immunostained with CB1R (BioWorld), IL-1β, fibronectin, and PPARγ 2 monoclonal antibodies, and immunohistochemical staining kits (BioGenex, San Ramon, CA). In some experiments, mesangial cells and podocytes were detected by probing smooth muscle actin and nephrin monoclonal antibodies and fluorescence FITC-and rhodamine-conjugated IgG as secondary antibodies. Sections probed by IgG were used as negative controls. The numbers of immunostained and total cells per high power field in each section were counted, and the percentage of positive cells was calculated.
In vitro high glucose treatment Rat mesangial cells (1×10 6 cells/well, six-well plate) with or without 100 μM WIN55212-2, 500 μM AM251, or 30 nM PD98059 were incubated in DMEM with 10 % fetal bovine serum and 35 mM D-glucose or 35 mM D-mannose (osmolarity control) for 48 h [21] .
Flow cytometry
Apoptotic cells were identified using Annexin V-FITC Apoptosis Detection Kit (Strong Biotech Corporation, Taipei, Taiwan) according to the manufacturer's instructions. Briefly, cell cultures (5×10 5 cells/mL) were mixed with staining solution containing Annexin V-FITC and followed by flow cytometry using 488 nm excitation. The number of cells positive for Annexin V staining was counted.
Transfection
Cells (3×10 5 cells/well, six-well plate) were incubated in DMEM and 10 % FBS till 70 % confluence and then washed with PBS. Each well was mixed with 2 mL transfection mixtures containing 0.25 mL Upit-mem TM , 0.03 mL Lipofectamin2000 TM (Invitrogen) and 20 μg/mL CB1R-AS, CB1R-S, or PPARγ2 siRNA (Panomics) for 6 h according to the manufacturer's instructions. Transiently transfected cells were incubated in DMEM and 10 % FBS at 37 C for 24 h. In some experiments, cells were stably transfected with dominant negative Ras (S17N) (Upstate Biotechnology, Lake Placid, NY) or PPARγ2 cDNA (Invitrogen, Carlsbad, CA). Stably transfected cells were incubated in DMEM, 10 % FBS and 600 mg/mL G418.
Western blotting
Renal tissue extracts and cell lysates were isolated and subjected to electrophoresis, blotted, and probed by antibodies against CB1R (Abcam, Cambridge, UK), IL-1β, fibronectin, PPARγ 2 , c-Jun, SOCS3, c-Ras, activated Ras, c-Jun, 
Results
Hyperglycemia increases glomerular fibrosis, inflammation, and CB1R signaling
We tested whether diabetes-mediated renal fibrosis was linked to CB1R signaling. Streptozotocin-induced diabetic rats had higher serum HbA1c levels (Fig. 1a) and kidney weight (Fig. 1b) at 8 weeks after induction of diabetes than the control rats, indicating successful induction of our model. Glomeruli in diabetic kidneys displayed hypertrophy and strong periodic acid-Schiff stain at 8 weeks after induction of diabetes (Fig. 1c) . Functional PCR array analyses showed that diabetes significantly increased the expression of 12 genes (CB1R, collagen I, collagen IV, fibronectin, IL-1β, IL-1 receptor antagonist, IL-6, TGF-β1, TNFα, Foxo1, Ras, and S100A9) and reduced the expression of 5 genes (NPY1R, NPY2R, NRG1, PPARγ2, and NGF) in renal tissues at 8 weeks after induction of diabetes (Fig. 1d) . We harvested isolated renal glomeruli and confirmed the mRNA expression of interest in the succeeding experiments. Hyperglycemia significantly increased the expression of CB1R, IL-1β, and fibronectin and concomitantly decreased PPARγ2 expression in glomeruli at 2 weeks after induction of diabetes (Fig. 1e ). Glomerular and tubular tissues strongly displayed CB1R immunostaining.
Mesangial cells strongly expressed IL-1β, and fibronectin but weakly displayed PPARγ2 immunostaining (Fig. 1f) . In the control group, mesangial cells as evidenced by smooth muscle actin and Thy1 immunoreactions (green fluorescence) and podocytes as demonstrated by nephrin and Wilms's tumor 1 immuno-fluorescence (green fluorescence) weakly expressed CB1R immunoreactivity (red fluorescence) (Fig. 1g) . Diabetic renal glomerular compartment had decreased mesangial cells and podocytes. Few podocytes and mesangial cells strongly displayed CB1R immunoreactions (Fig. 1g) CB1R signaling promotes fibrosis and inflammation of renal tissue in mice
We tested whether a gain of CB1R function affected inflammation or fibrosis in renal tissues. CB1R transgenic mice 2 and 9 months old had increased kidney weight (Fig. 2a) and increased the expression of CB1R, IL-1β, and fibronectin in whole renal tissue extracts (Fig. 2b ) and isolated glomerular tissues (Fig. 2c ) compared to wild-type mice. Glomeruli in the CB1R transgenic mouse kidneys strongly displayed periodic acid-Schiff stain and CB1R and fibronectin immunostaining ( Fig. 2d and Supplemental data 2). Mice, 9 months old, had higher body weight than those of 2-month-old mice. Overexpression of CB1R did not significantly change blood glucose, triglyceride, creatinine, or GOT levels (Supplemental data 2).
Loss of CB1R function alleviates diabetes-mediated renal deterioration
We verified whether CB1R blockade affected the hyperglycemia-mediated renal glomerular deterioration. We administered CB1R-AS or inverse agonist AM251 to diabetic rats for 5 weeks. Neither CB1R-AS nor AM251 treatment had any significant effect on blood glucose in diabetic rats (Table 1) . However, treatment with 250 μg/kg per day of AM251 significantly reduced body weight of diabetic animals (data not shown), so a lower dose (50 μg/kg per day) was used for subsequent experiments. CB1R-AS or AM251 treatment significantly ameliorated the hyperglycemia-induced increase of kidney weight (Fig. 3a) and decreased CB1R expression in whole renal tissue extracts (Fig. 3b ) and isolated glomerular tissues (Fig. 3c) . Mesangial cells in the diabetes group strongly displayed CB1R immunostaining and apoptotic cell marker TUNEL staining. Few cells expressed CB1R immunoreactivity and TUNEL staining after CB1R-AS and AM251 treatment (Fig. 3d) . Treatment with CB1R-AS or AM251 significantly reduced the hyperglycemia-induced increase of IL-1β and fibronectin expression and restored PPARγ2 expression in whole renal tissue extracts (Fig. 3b) and isolated glomerular tissues (Fig. 3c) . Glomeruli weakly displayed periodic acid staining, and mesangial cells strongly expressed PPARγ2 immunostaining and weakly displayed IL-1β, fibronectin, and TUNEL staining in diabetic kidneys after CB1R-AS and AM251 treatment (Fig. 4 and Table 1 ). Sense controls CB1R-S treatment had no significant effect on the hyperglycemia-mediated CB1R, IL-1β, fibronectin or PPARγ2 expression in renal tissue.
PPARγ agonist decreases CB1R expression in diabetic renal glomeruli CB1R reportedly regulates PPARγ signaling in various cell types [16, 17] . A bioinformatics search (Transcription Element Search System; www.cbil.upenn/cgi-bin/tess/tess) indicates that PPARγ 2 is predicted to regulate CB1R expression. We investigated whether diabetes enhancement of CB1R expression was linked to PPARγ 2 signaling in diabetic kidneys. Activation of PPARγ2 by rosiglitazone significantly restored PPARγ2 expression but decreased the promotional effects of hyperglycemia on the expression of CB1R, IL-1β, and fibronectin in whole renal tissue extracts (Fig. 5a ) and isolated glomerular tissues (Fig. 5b) . Mesangial cells weakly expressed CB1R immunostaining after the rosiglitazone treatment (Fig. 5c ). Glomeruli weakly displayed periodic acid-Schiff staining after rosiglitazone treatment (Fig. 5d) . c-Jun and suppressor of cytokine signaling 3 (SOCS3) are important transcription factors to regulate fibrotic matrix synthesis and inflammation activities in various tissues. We tested whether CB1R or PPARγ 2 signaling modulated c-Jun or SOCS3 expression in diabetic renal. Hyperglycemia significantly increased c-Jun and SOCS3 expression in whole renal tissue extracts (Fig. 6a ) and isolated glomerular tissues (Fig. 6b) . These effects were attenuated after CB1R-AS, AM251 or rosiglitazone treatment. CB1R antagonism or PPARγ 2 activation significantly reduced the hyperglycemiainduced promotion of TGF-β1, TNF-α, and IL-6 expression in the isolated glomerular tissues (Fig. 6c ).
Ras and ERK mediated CB1R promotion of fibrosis and apoptosis in mesangial cells
We investigated the molecular mechanism underlying CB1R modulation of inflammation and fibrosis in mesangial cells. High glucose significantly increased the levels of CB1R (Fig. 7a) , active Ras, phosphorylated ERK, and SOCS3 but decreased PPARγ2 level (Fig. 7b) in association with the increased expression of IL-1β, TGF-β1, and fibronectin (Fig. 7d) . These effects were reduced by CB1R-AS or AM251 treatment. Treatment with WIN55212-2 alone increased Ras, ERK, and SOCS3 signaling and inflammatory and fibrotic factor expression. Treatments with sense control CB1R-S or AM251 did not significantly change the promotional effects of high glucose on the expression of CB1R. Actin levels were not changed in the CB1R-AS or CB1R-S group, indicating that CB1R interference by CB1R-AS was not caused by general suppression of gene expression. High glucose or CB1R modulators had no significant effects on the levels of phosphorylated JNK or phosphorylated p38MAPK in cell cultures ( Fig. 7 and Supplemental data 3). Osmolarity control mannose did not significantly change the expression of CB1R or signaling molecules of interest. (Fig. 7) . Inactivation of Ras by the dominant negative Ras cDNA or reduction The symbol * indicates significant difference vs. NC group, and the symbol # indicates significant difference vs. DM group (P<0.05). Ros rosiglitazone of phosphorylated ERK levels by PD98059 (Fig. 7c) significantly decreased the high glucose-induced enhancement of IL-1β, fibronectin, and TGF-β1 expression (Fig. 7d) . High glucose or WIN55212-2 treatment significantly increased apoptosis in cell cultures as evidenced by annexin V staining, whereas CB1R-AS or AM251 treatment attenuated the high glucose-mediated apoptosis reactions in mesangial cells (Fig. 8) .
Gain of PPARγ 2 function significantly reduced the high glucose-induced promotion of CB1R, c-Jun, and SOCS3 levels (Fig. 9a) and the expression of IL-1β, TGF-β1 (Fig. 9c), and fibronectin (Fig. 9b) . Knockdown of PPARγ 2 alone significantly increased the expression of CB1R, SOCS3, IL-1β, TGF-β1, and fibronectin (Fig. 9 ) in mesangial cultures.
Discussion
Our results indicated that hyperglycemia induced glomerular fibrosis and is concomitant with the upregulated CB1R signaling and inflammatory cytokines in diabetic renal tissues. CB1R signaling is found to mediate hyperglycemia-induced renal podocyte dysfunction [9] , palmitic acid-induced renal tubular cell apoptosis [10] and reactive oxygen radicalinduced kidney cell apoptosis and renal dysfunction [11] . However, the mechanistic actions of CB1R in the mesangial cells of diabetic renal glomerular microenvironments have seen limited investigations. We are the first group to report that interruption of CB1R signaling protected glomerular tissues against the deleterious effects of hyperglycemia on PPARγ2 signaling and attenuated inflammation and fibrosis activities in diabetic kidneys. High glucose-mediated CB1R activation triggered fibrogenic transcription factor c-Jun and inflammation regulator SOCS3 that increased the biosynthesis of extracellular matrix and proinflammatory cytokines in mesangial cells. Increment in CB1R action on renal glomerular microenvironments provides new molecular insight into the deleterious actions of hyperglycemia on mesangial cell homeostasis in the pathogenesis of diabetes-mediated renal damage. CB1R antagonism for reduction of excessive extracellular matrix deposit and inflammation in glomerular This study, which employed functional arrays, lasercaptured microdissection, quantitative RT-PCR, and immunohistochemistry, indicated that increased CB1R levels The symbol * indicates a significant difference vs. vehicle group and the symbol # indicates significant difference vs. high glucose group (P<0.05), respectively. Man mannose; HG high glucose; SC scrambled control; AS CB1R antisense oligonucleotide; S CB1R sense oligonucleotide; AM AM251; WIN WIN55212-2; DN-Ras dominant negative Ras; PD PD98059 coincided with the intensive extracellular matrix accumulation and inflammation as evidenced by prominent hypertrophy and periodic acid-Schiff stain, as well as increased IL-1β and fibronectin abundances in diabetic renal glomeruli. Blockage of CB1R signaling by CB1R-AS or AM251 ameliorated the adverse effects of hyperglycemia on glomerular integrity suggesting that CB1R signaling contributes to diabetes-induced loss of glomerular microarchitecture. CB1R signaling actively responds to high glucose stress [22] and promotes apoptosis and fibrosis reactions in various tissue types [23, 24] . In the Renal mesangial cells, podocytes, and tubular cells strongly displayed CB1R immunoreactivity. In vitro CB1R inverse agonist, AM251, protected against high glucose enhancement of IL-1β, TGF-β1, and fibronectin expression in mesangial cells, consistent with our in vivo phenomenon in diabetic renal tissue. We suggest that CB1R signaling in mesangial cells participates in the hyperglycemia-mediated glomerular inflammation and fibrosis in kidneys. Previous studies demonstrated that CB1R immunostaining predominantly exists in renal glomerular podocytes. CB1R antagonism by 1 mg/kg per day AM251 [11] or CB2 activation by agonist AM1241 [25] had no effect on body weight, TGF-β1, or fibronectin expression in glomerular microenvironments of diabetic mouse kidneys after administration for 14 weeks. In our study, the glomeruli had significant inflammation and fibrosis in diabetic kidneys of rats. These phenomena were diminished after 50 g/kg per day of AM251 treatment for 5 weeks. Nevertheless, rats lost body weight after administration of 250 μg/kg per day AM251. The deleterious effects of high concentration of AM251 treatment on rat body weight and behavior is a significant concern [26]. Mesangial cell dysfunction is a prominent reaction during the early stages of streptozotocin-or high fat-induced diabetic renal injury [27, 28] and contributes to glomerulus hypertrophy and accumulation of extracellular matrix [29] . We suggest that different CB1R abundances in renal cells of rat and mouse renal glomeruli and physiological responses to AM251 administration may be due to different stages of diabetic nephropathy or genetic background of the experimental animals. The varying distribution of CB1R immunoreactivity in glomerulus microenvironments is also suggestive of the complexity of hyperglycemia-mediated renal injury. In other words, different renal cell populations may have distinct roles in the pathogenesis of diabetic glomerulopathy.
The mechanistic events underlying the CB1R signalinginduced inflammation and fibrosis in glomerular mesangial cells have seldom been explored. CB1R signaling activated Ras and ERK signaling cascades in high glucose-stressed mesangial cells. High glucose impairs PPARγ action [14] , activates Ras and ERK signaling-dependent synthesis of TGF-β1 and fibronectin in renal cells [18, 20, 21] , and participates in CB1R regulation of angiogenic reactions in . Scheme of CB1R signaling promotion of fibrosis and inflammation reactions in renal mesangial cells exposed to hyperglycemia (c). Data are expressed as mean±SEM calculated from at least three experiments. The symbol * indicates significant difference vs. vehicle group, and the symbol # indicates significant difference vs. high glucose group (P<0.05), respectively. HG high glucose; SC scrambled control; cDNA PPARγ2 cDNA; siRNA PPARγ2 siRNA vascular endothelial progenitor cells [30] . Activation of CB1R stimulates p38 signaling in adipose tissue of high fat-fed mice [31] and JNK signaling in mice with diabetic retinopathy [32] . In this study, high glucose stress or activation of CB1 did not affect p38 MAPK or JNK phosphorylation in mesangial cells (Supplemental data 3). The phenomena of high glucose stress on the levels of phosphorylated p38 or phosphorylated JNK were in line with those in previous studies [18] . The diverse actions of high glucose stress or CB1R signaling on ERK, p38 MAPK, and JNK activation may be due to varying cell types in vitro models.
Notably, blockage of CB1R signaling restored PPARγ 2 signaling in the renal glomeruli of diabetic animals and high glucose-treated mesangial cells. Knockdown of PPARγ 2 mimicked the promotional effects of high glucose on the CB1R signaling in mesangial cell cultures, suggesting that CB1R negatively regulates the PPARγ 2 signaling in mesangial cells. Activation of PPARγ 2 retards aged-induced renal dysfunction [15] . Aged CB1R knockout mice have high bone mass and PPARγ 2 expression [33] . We found that gain of PPARγ 2 function protected renal tissue against hyperglycemia promotion of CB1R, fibrogenic transcription c-Jun, and inflammation regulator SOCS3 signaling, and thereby stabilizing glomerular integrity. CB1R reportedly activates PPARγ 2 to control tissue remodeling and inflammation [34] . This study provides the first indication that hyperglycemia disturbs the balances between CB1R and PPARγ 2 actions in glomeruli, leading to excessive fibrogenesis in the course of glomerulopathy.
Taken together, our results indicate that CB1R signaling contributes to intensive inflammation and fibrosis in renal glomeruli and mesangial cells. Inhibition of CB1R signaling abrogated high glucose-induced glomerular deterioration. This study provides a novel mechanistic explanation of high glucose-induced CB1R activation reciprocally with PPARγ 2 depression and renal mesangial fibrosis (Fig. 8c) . Regulation of CB1R activity can be used an alternative therapeutic strategy for the maintenance of renal microstructure integrity in the presence of high glucose stress.
